amantadine
E229732
NMDA receptor antagonist
adamantane derivative
antiparkinsonian agent
antiviral drug
dopaminergic agent
Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| amantadine canonical | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
NMDA receptor antagonist
ⓘ
adamantane derivative ⓘ antiparkinsonian agent ⓘ antiviral drug ⓘ dopaminergic agent ⓘ |
| availableAs |
oral capsule
ⓘ
oral syrup ⓘ oral tablet ⓘ |
| contraindicatedIn |
severe renal impairment
ⓘ
untreated angle-closure glaucoma ⓘ |
| developedInDecade | 1960s ⓘ |
| eliminationRoute | renal excretion ⓘ |
| hasATCCode |
J05BB01
ⓘ
N04BB01 ⓘ |
| hasBrandName | Symmetrel ⓘ |
| hasCASNumber | 768-94-5 ⓘ |
| hasChemicalFormula | C10H17N ⓘ |
| hasIUPACName | 1-adamantanamine ⓘ |
| hasMolarMass | 151.25 g/mol ⓘ |
| isObsoleteFor |
routine influenza A prophylaxis
ⓘ
routine influenza A treatment ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mayCauseAdverseEffect |
confusion
ⓘ
constipation ⓘ dry mouth ⓘ hallucinations ⓘ insomnia ⓘ livedo reticularis ⓘ orthostatic hypotension ⓘ peripheral edema ⓘ urinary retention ⓘ |
| mechanismOfAction |
increased dopamine release
ⓘ
inhibition of dopamine reuptake ⓘ interference with influenza A viral uncoating ⓘ noncompetitive NMDA receptor antagonism ⓘ weak anticholinergic effect ⓘ |
| pregnancyCategoryUS | C ⓘ |
| requiresDoseAdjustmentIn | renal impairment ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
NMDA receptor
ⓘ
dopaminergic neurons ⓘ |
| usedFor |
Parkinson's disease
ⓘ
Parkinsonian bradykinesia ⓘ Parkinsonian dyskinesia ⓘ Parkinsonian rigidity ⓘ Parkinsonian tremor ⓘ drug-induced extrapyramidal symptoms ⓘ influenza A infection ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.